Is CBD Safe? Facts and Myths About Using CBD

Cannabidiol (CBD) has transitioned from a niche supplement to a global market worth approximately $7.7 billion, according to a 2023 Grand View Research report. However, with popularity comes concerns. Is this compound really safe? Can it be combined with medications? What does science say, and what is just a marketing myth?

In this article, we will examine the safety of CBD through the lens of hard data: the WHO ECDD report from 2018, pharmacological reviews, and official FDA statements. We debunk the five most popular myths, discuss real risks, and explain what to look for when choosing a product. This is not a promotional article. It is a reliable compendium of knowledge based on peer-reviewed research.

Note: The content is for educational purposes only and does not constitute medical advice. Before starting CBD supplementation, especially when using chronic medications, during pregnancy, or while breastfeeding, consult your doctor.

Is CBD safe according to WHO? A brief answer

Yes, CBD is generally safe. The WHO Expert Committee on Drug Dependence (WHO ECDD) in its Critical Review from 2018 stated that "cannabidiol is generally well tolerated, has a good safety profile" and does not exhibit potential for abuse or dependence ([WHO ECDD, 2018](https://www.who.int/publications/i/item/who-ecdd-40-cbd-critical-review)).

This verdict changed the global regulatory landscape. Following the WHO report, many countries, including EU member states, liberalized their approach to CBD-containing products. However, this does not mean that the substance is without risks. The report lists specific caveats: possible drug interactions, variability in the quality of commercial products, and a lack of long-term studies on daily use.

In our sales practice, we observe that customers are increasingly asking not just about CBD itself, but about its source, certifications, and the composition of full-spectrum extracts. This reflects a shift in awareness over the past two years.

What exactly did WHO say?

The full text of the Critical Review from June 2018 contains several key conclusions. CBD does not produce the psychoactive effects typical of THC. It does not cause physiological withdrawal symptoms. It does not increase substance-seeking behavior in laboratory animals in self-administration tests. When side effects occur, they are mild and transient.

However, WHO emphasized that the data mainly concern CBD isolate used in controlled conditions. Products sold to consumers may contain impurities, inconsistent concentrations, or undeclared substances.

review of scientific publications on cannabinoids

According to the WHO ECDD Critical Review from 2018, pure cannabidiol "is generally well tolerated, has a good safety profile" and "does not exhibit effects indicating potential for abuse or dependence". The committee recommended not including CBD under international drug conventions ([WHO, 2018](https://www.who.int/publications/i/item/who-ecdd-40-cbd-critical-review)).

Myth 1: Does CBD give a "high" like marijuana?

False. CBD is not psychoactive in the common understanding of the word. Unlike tetrahydrocannabinol (THC), cannabidiol does not directly bind to CB1 receptors in the brain. According to the review by Iffland and Grotenhermen (2017) published in "Cannabis and Cannabinoid Research," CBD does not induce euphoria, perceptual disturbances, or cognitive impairment ([Iffland & Grotenhermen, 2017](https://pubmed.ncbi.nlm.nih.gov/28861514/)).

The mechanism of action of CBD is complex. The substance modulates the activity of cannabinoid receptors instead of directly stimulating them. It also affects serotonin receptors 5-HT1A, vanilloid receptors TRPV1, and GPR55 receptor. This "distributed" mode of action explains the wide range of effects while simultaneously accounting for the lack of a typical "high".

Why do people confuse CBD with THC?

The reason is the source plant. Both compounds come from hemp (Cannabis sativa). Visually, dried CBD flowers look identical to THC flower. They smell similar. This coincidence of sensory similarities fuels the myth.

The difference lies in chemistry and law. Industrial hemp, from which CBD is extracted, contains up to 0.3% THC according to Polish legislation. Medical or recreational marijuana often contains 15-25% THC. That's a significant difference.

The review by Iffland and Grotenhermen from 2017 in "Cannabis and Cannabinoid Research" confirms that CBD does not exhibit psychotomimetic effects even at high doses of 1500 mg/day, and the safety profile is "clearly better" than many medications ([Iffland & Grotenhermen, 2017](https://pubmed.ncbi.nlm.nih.gov/28861514/)).

Myth 2: Is CBD legal everywhere and without restrictions?

False. The legal status of CBD varies significantly between jurisdictions. In the European Union, cannabidiol gained Novel Food status in 2019, which means that every food product containing CBD must be authorized before being marketed. According to the European Commission database, by the end of 2023, no Novel Food application for CBD has been fully approved, although several are in the process.

In Poland, the situation is specific. CBD oils and cosmetics are legally available if they come from industrial hemp containing less than 0.3% THC. The legal basis is the Act of July 29, 2005 on Counteracting Drug Addiction and its subsequent amendments. The 0.3% THC limit has been in effect since March 2022; previously, it was 0.2%.

What does Novel Food status mean?

Novel Food is a category of food that was not commonly present in the EU before May 15, 1997. For CBD, this means that although the substance itself is legal, every food product (capsules, gummies, beverages) requires a separate authorization procedure with EFSA.

Practical consequence: most CBD oils on the market operate in a regulatory gray area as "extracts" or cosmetics, not dietary supplements. This is a temporary solution until the Novel Food procedures are completed.

Polish regulations in practice

When buying CBD in Poland, check three elements. First, the declared THC content below 0.3%. Second, a Certificate of Analysis (COA) confirming this value laboratory-wise. Third, the source of hemp – it should come from varieties listed in the EU Common Catalogue of Varieties of Agricultural Plant Species.

The Polish Act of July 29, 2005 on Counteracting Drug Addiction allows the cultivation and processing of industrial hemp containing up to 0.3% delta-9-THC in the dry mass of flower buds. This limit was raised from 0.2% by the amendment in March 2022, harmonizing Polish law with most EU countries.

Myth 3: Does CBD have no side effects?

Not true. CBD has side effects, although they are usually mild. The most comprehensive review by Iffland and Grotenhermen (2017) analyzing over 130 clinical studies identifies four most common adverse effects: fatigue and drowsiness, diarrhea, changes in appetite or weight, and dry mouth ([Iffland & Grotenhermen, 2017](https://pubmed.ncbi.nlm.nih.gov/28861514/)).

The frequency of these symptoms increases with dosage. In clinical studies on Epidiolex (approved CBD medication) conducted by Devinsky et al., where patients received 20 mg/kg body weight daily, adverse effects occurred in a significantly higher percentage of participants than in the placebo group. These doses range from 1000-1500 mg daily, much higher than typical consumer supplementation of 25-50 mg.

Most common side effects and how to recognize them

• Drowsiness and fatigue: especially at doses above 50 mg or when taken in the evening. Some users consider this effect desirable in the context of sleep issues.
• Diarrhea and stomach discomfort: common with MCT oil as a carrier, especially in individuals with sensitive digestive systems.
• Dry mouth: a class effect of the entire group of cannabinoids, resulting from modulation of saliva secretion.
• Changes in appetite: an increase in some users, a decrease in others. The direction can be individual.
• Changes in liver tests: in high clinical doses, elevations in ALT and AST enzymes were observed in about 10-15% of patients.

When do side effects require a response?

Most symptoms resolve spontaneously after a few days or with a dose reduction. Concerning symptoms include: persistent diarrhea lasting more than a week, jaundice that may indicate liver problems, significant drowsiness preventing daily functioning. In these cases, CBD should be discontinued and a doctor consulted.

From our customer service experience, about 80% of reports of "side effects" are resolved by simply reducing the dose by half and switching to evening administration.

The review by Iffland and Grotenhermen in "Cannabis and Cannabinoid Research" (2017) lists the most commonly reported side effects of CBD: fatigue (occurring in 5-20% of patients depending on the dose), diarrhea, changes in appetite and body weight, and interactions with other medications ([Iffland & Grotenhermen, 2017](https://pubmed.ncbi.nlm.nih.gov/28861514/)).

Myth 4: Does CBD not interact with medications?

False. CBD is an active inhibitor of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. According to the review by Brown and Winterstein published in "Journal of Clinical Medicine" (2019), these two metabolic pathways are responsible for the breakdown of about 60% of all prescription medications, making interactions a significant clinical risk ([Brown & Winterstein, 2019](https://www.mdpi.com/2077-0383/8/7/989)).

The mechanism is predictable. CBD blocks liver enzymes, slowing down the metabolism of drugs. This leads to increased concentrations in the blood, effectively resulting in "overdose" at normal therapeutic doses. In clinical practice, this primarily concerns drugs with a narrow therapeutic window.

List of high-risk interaction medications

• Warfarin and other anticoagulants: CBD may enhance the anticoagulant effect, raising INR and the risk of bleeding. Documented clinical cases required a reduction in warfarin dosage.
• Clobazam (anticonvulsant): in studies on Epidiolex, a threefold increase in the concentration of the active metabolite N-desmethylclobazam was observed.
• Tacrolimus (immunosuppressant): cases of significant concentration increases in transplant patients have been reported.
• Some antidepressants: particularly those from the SSRI group metabolized by CYP2C19 (escitalopram, sertraline).
• Statins: especially atorvastatin and simvastatin, where increased concentrations raise the risk of myopathy.
• Cyclosporine: another immunosuppressant with a narrow therapeutic window.

Grapefruit rule – practical tip

There is a practical heuristic. If your medication's leaflet warns "do not consume with grapefruit juice," there is a high chance that the drug is metabolized by CYP3A4. The same warning applies to CBD. Grapefruit juice and CBD block similar enzymes.

Most articles about CBD overlook the fact that the risk of interactions increases non-linearly with dosage. At 10-25 mg daily, the impact on liver enzymes is minimal for most people. At 600 mg+ (epileptic doses), interactions become clinically significant for nearly every patient on medications metabolized by CYP3A4.

Brown and Winterstein in "Journal of Clinical Medicine" (2019) identify 139 drugs with potentially clinically significant interactions with CBD, of which 57 require close monitoring. The most common interaction pathways are CYP3A4 enzymes (40% of interactions) and CYP2C19 (28%) ([Brown & Winterstein, 2019](https://www.mdpi.com/2077-0383/8/7/989)).

Myth 5: Are all CBD products the same?

Far from the truth. A study by Bonn-Miller et al. published in the prestigious JAMA in 2017 analyzed 84 CBD products sold online. The results were devastating: only 31% of products had CBD content consistent with the label declaration. The rest were underreported (26%) or overreported (43%) ([Bonn-Miller et al., 2017](https://jamanetwork.com/journals/jama/fullarticle/2661569)).

Worse still, THC was detected in 21% of samples, despite claims of "THC-free." Although the concentrations were low, for individuals undergoing drug tests, pregnant women, or patients who react psychoactively even to low doses, this poses a real risk.

Lack of quality regulation – practical consequences

The CBD market operates in the EU and Poland under conditions of incomplete regulation. There are no mandatory GMP standards for supplements, standardized analytical methods, or official reference laboratories. Manufacturers publishing COAs do so voluntarily, not out of obligation.

This creates an asymmetry of information. Two "5% CBD" oils may contain anywhere from 2% to 7% actual cannabidiol. They may be pure or contain heavy metals, pesticides, residual solvents.

Contaminants – what specifically to test for?

Hemp is a bioaccumulator plant. It absorbs heavy metals (cadmium, lead, mercury, arsenic) from the soil more effectively than most crops. This botanical characteristic is used in phytoremediation but problematic in food and supplement production.

• Heavy metals: cadmium, lead, mercury, arsenic – limits according to EU Commission Regulation 2023/915.
• Pesticides: especially glyphosate, neonicotinoids used in illegal cultivation.
• Residual solvents: ethanol, butane, hexane depending on the extraction method.
• Mycotoxins: aflatoxins B1, ochratoxin A from mold due to improper drying.
• Microbiology: molds, coliform bacteria, salmonella.

consumer guide to quality

The study by Bonn-Miller et al. published in JAMA in 2017 showed that of the 84 tested CBD products sold online, 69% were mislabeled regarding CBD content, and 21% contained undeclared THC ([Bonn-Miller et al., 2017](https://jamanetwork.com/journals/jama/fullarticle/2661569)).

Is CBD safe during pregnancy and breastfeeding?

No, it is NOT recommended. The FDA issued an official statement in October 2019 warning pregnant and breastfeeding women against using products containing CBD and THC. The reason is insufficient safety data and signals from animal studies suggesting potential effects on fetal development ([FDA, 2019](https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis)).

This position is shared by other agencies. The Polish Society of Gynecologists and Obstetricians has not issued a dedicated opinion on CBD but generally advises against substances with incomplete safety profiles during pregnancy. The European Medicines Agency (EMA) in the documentation for Epidiolex also indicates a lack of recommendations during pregnancy.

What exactly do studies show?

Direct data in humans are limited for obvious ethical reasons. Animal studies suggest several risk mechanisms: effects on fetal nervous system development, potential hormonal disturbances, possible transfer to breast milk. CBD is a lipophilic substance, accumulating in fatty tissues, including milk.

The FDA also emphasizes the issue of contaminants. Even if pure CBD were found to be safe during pregnancy, commercial products may contain THC, pesticides, or heavy metals particularly harmful to the developing fetus.

Practical recommendations

If you are planning a pregnancy, discontinue CBD supplementation at least a month before stopping contraception. If you become pregnant while using CBD, do not panic, but stop immediately and inform your gynecologist. During breastfeeding, refrain from CBD until lactation is complete.

The FDA stated in a consumer communication from October 2019: "high exposure to CBD in mothers caused reproductive problems in the offspring of laboratory animals." The agency "strongly advises against" the use of CBD by pregnant and breastfeeding women ([FDA, 2019](https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis)).

How to properly dose CBD? The titration method

The golden rule is: start low, increase slowly. According to clinical guidelines presented in the review by Iffland and Grotenhermen (2017), a safe starting dose for a healthy adult is 10-25 mg of CBD daily. The dose is gradually increased by 5-10 mg every 5-7 days, monitoring the body's response and any side effects.

This method is called titration. It is used in clinical pharmacology for substances with individually variable responses. CBD is a classic example – two people with the same body weight may require doses differing by 5 times to achieve a similar effect.

Reference dosing table

• Micro dose (5-15 mg/day): general wellness support, mild stress, beginning supplementation.
• Standard dose (15-50 mg/day): sleep issues, moderate anxiety, muscle discomfort.
• Average dose (50-150 mg/day): chronic pain, significant anxiety, therapeutic support under medical supervision.
• High dose (150-800 mg/day): only under medical supervision, clinical indications.
• Clinical dose (800-1500 mg/day): refractory epilepsy, hospital therapy, Epidiolex medication.

Practical calculations for oils

A 5% CBD oil in a 10 ml bottle contains 500 mg of cannabidiol. A standard dropper is about 1 ml, which is 50 mg of CBD. One drop is approximately 2.5 mg of CBD. For an initial dose of 10 mg daily, you need 4 drops of 5% oil.

In the case of 10% oil, the numbers double: 10 ml contains 1000 mg, a drop is 5 mg of CBD. A 15% oil (like Cannova CBG 15%) has 1500 mg in 10 ml, a drop is 7.5 mg of the active substance.

When to expect effects?

Sublingual oil usually takes effect in 15-45 minutes, lasting 4-6 hours. Capsules and edibles work slower (45-90 minutes) but last longer (6-8 hours) – they undergo first-pass metabolism in the liver. Therapeutic effects (e.g., for sleep, anxiety) usually require 2-4 weeks of regular use.

Analysis of repeat customer orders shows that over 70% of individuals ultimately stabilize their dose in the range of 25-50 mg daily, regardless of initial ambitions for higher doses.

Clinical guidelines based on the review by Iffland and Grotenhermen (2017) recommend starting CBD supplementation at a dose of 10-25 mg daily, increasing by 5-10 mg every 5-7 days using the titration method. Doses above 600 mg/day should be used only under medical supervision due to the risk of drug interactions.

Is CBD safe for children? The case of Epidiolex

Partially yes, but only for specific medical indications. The drug Epidiolex (pharmaceutical-grade cannabidiol) was approved by the FDA in 2018 for the treatment of two rare forms of childhood epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. The basis for registration was a study by Devinsky et al. published in the "New England Journal of Medicine" (2017), showing a 39% reduction in seizure frequency in children treated with CBD ([Devinsky et al., 2017](https://www.nejm.org/doi/full/10.1056/NEJMoa1611618)).

This shows two things. First, CBD has proven efficacy and an acceptable safety profile even in children. Second, this applies only to specific clinical indications, in pharmaceutical form, under strict supervision of a pediatric neurologist.

CBD supplementation in healthy children – expert position

There is no evidence justifying routine CBD supplementation in healthy children. Long-term safety data are limited, the endocannabinoid system in developmental age is still under research, and interactions with the hormonal system may have unknown consequences.

The American Academy of Pediatrics (AAP) advises against the use of CBD products in children outside of approved clinical indications. Similar positions are held by European pediatric societies.

When is CBD justified for a child?

• Refractory epilepsy: including Dravet and Lennox-Gastaut syndromes – Epidiolex as a prescription medication.
• Tuberous sclerosis: another indication for Epidiolex, added by the FDA in 2020.
• Some cancers: only as supportive treatment under the supervision of a pediatric oncologist.

The study by Devinsky et al. published in the "New England Journal of Medicine" in 2017 showed that adding CBD (20 mg/kg/day) to standard treatment for children with Dravet syndrome reduced the median monthly number of seizures from 12.4 to 5.9, a 39% reduction compared to 13% in the placebo group ([Devinsky et al., 2017](https://www.nejm.org/doi/full/10.1056/NEJMoa1611618)).

Is CBD safe for pets?

Research on CBD in companion animals is in the early stages. According to an analysis published in "Frontiers in Veterinary Science" in 2018 by Gamble et al., a dose of 2 mg/kg twice daily reduced pain and increased comfort in 80% of dogs with osteoarthritis. However, the American Veterinary Medical Association warns that the data is preliminary and many safety aspects remain unstudied.

The key difference between humans and animals is metabolic sensitivity. Dogs have significantly more cannabinoid receptors in their brains than humans, making them more sensitive to THC. Any CBD product for pets must have laboratory-confirmed zero THC concentration, not just below 0.3%.

What to absolutely avoid?

Cats are particularly sensitive. They lack some liver enzymes that metabolize plant substances. Oils for cats require special formulation, lower doses, and careful titration. Some CBD oils for humans contain xylitol as a sweetener – this substance is deadly for dogs even in small doses.

Chocolate, onions, garlic (sometimes in flavored products), essential oils (eucalyptus, tea tree) – all these additives require checking in products intended for animals.

Dosage for dogs – approximate values

• Small dog (up to 10 kg): 2-5 mg of CBD once or twice daily.
• Medium dog (10-25 kg): 5-15 mg of CBD once or twice daily.
• Large dog (25-45 kg): 15-25 mg of CBD once or twice daily.
• Very large dog (over 45 kg): 25-40 mg of CBD once or twice daily.

The study by Gamble et al. published in "Frontiers in Veterinary Science" in 2018 showed that CBD at a dose of 2 mg/kg twice daily significantly reduced pain complaints and increased activity in 80% of dogs with osteoarthritis, with no reported serious side effects during 4 weeks of observation.

What to check with the CBD manufacturer before purchase?

According to a 2017 JAMA study, 69% of CBD products on the market are mislabeled ([Bonn-Miller et al., 2017](https://jamanetwork.com/journals/jama/fullarticle/2661569)). This makes verifying the manufacturer a critical step in the purchase. Five key elements to check: Certificate of Analysis (COA), source of hemp, extraction method, contamination testing, and company transparency.

Reputable manufacturers publish all this information on their website. The absence of even one element is a red flag. In our assessment, it is worth investing in products from companies that conduct tests in independent, accredited third-party laboratories, not their own.

What is COA and how to read it?

A Certificate of Analysis (COA) is a laboratory report summarizing the composition and purity of a specific batch of the product. It should include: cannabinoid content (CBD, CBDA, THC, CBG, CBN, CBC), terpene profile, results of tests for heavy metals, pesticides, microbiology, and residual solvents.

Check the test date (it should correspond to the production date of the batch) and the name of the laboratory (is it accredited, e.g., ISO 17025). If the COA is old or anonymous, that is a reason for caution.

Questions for the manufacturer

• Where does hemp come from? Preferably from the EU, certified organic, known variety from the Common Catalogue.
• What extraction method? The cleanest is supercritical CO2 extraction, acceptable ethanol extraction.
• Full spectrum, broad spectrum, or isolate? Each has its pros and cons – full spectrum may be more effective, isolate has zero THC.
• What carrier? Most commonly MCT oil from coconut or hemp seed oil.
• Does it publish COA? Lack of COA on the site indicates a lack of transparency.

Recommended products with verifiable origin

In the hemp store u Bucha, you will find several verified items, each with an available Certificate of Analysis:

• SOOL CBD 5% 10ml (76 PLN): broad spectrum oil 500 mg CBD, a good start for beginners, 2.5 mg per drop. Link: SOOL CBD 5%.
• SOOL CBD 10% 10ml (99 PLN): the same manufacturer, twice the concentration 1000 mg CBD, for experienced users. Link: SOOL CBD 10%.
• Cannova CBG 15% (240 PLN): oil with cannabigerol (CBG), not CBD, an alternative cannabinoid with a different action profile, 1500 mg in 10 ml. Link: Cannova CBG 15%.
• Mars CBD Flower 9% (59 PLN): hemp flower for vaporization, an alternative for those preferring inhalation over oil. Link: Mars Dry CBD 9%.

The study by Bonn-Miller et al. published in JAMA (2017) showed that only 31% of the 84 tested CBD products had content consistent with the label declaration, highlighting the critical role of the Certificate of Analysis (COA) and a transparent production process in choosing a trusted supplier ([Bonn-Miller et al., 2017](https://jamanetwork.com/journals/jama/fullarticle/2661569)).

Polish regulations regarding CBD – what is worth knowing?

In Poland, CBD products remain legal as long as they contain THC below 0.3% in dry mass. The legal basis is the Act of July 29, 2005 on Counteracting Drug Addiction (Journal of Laws 2005 No. 179 item 1485) with subsequent amendments. The last significant change in March 2022 raised the limit from 0.2% to 0.3% THC, harmonizing the law with most EU countries.

The legal status applies only to industrial hemp from varieties listed in the EU register. Cannabis indica and varieties with higher THC content remain on the list of controlled substances and require a permit for medical use.

What can you legally buy?

Legally available are: CBD oils, CBD cosmetics, CBD flower for vaporization (from industrial varieties), food-grade hemp seeds, hemp fiber. Prescription medical marijuana (only from a pharmacy with a prescription), any products with THC above 0.3%, THC concentrates, extracts from unregistered varieties remain prohibited without a prescription.

Controls and consumer risks

Penalties for possessing products with THC above 0.3% are serious – ranging from fines to 3 years of imprisonment (Article 62 of the Act). Therefore, it is crucial to buy only from verified suppliers with a current COA confirming compliance with the limit.

In practice, inspections by tax and sanitary authorities focus on the retail market, checking label compliance with actual content. The responsibility for compliance primarily rests with the seller, but a consumer knowingly purchasing an illegal product also bears consequences.

The Polish Act of July 29, 2005 on Counteracting Drug Addiction allows products from industrial hemp containing up to 0.3% delta-9-tetrahydrocannabinol. This limit has been in effect since March 2022, previously it was 0.2%. CBD products meeting these criteria are legal for consumer sale.

FAQ – frequently asked questions about CBD safety

Can you overdose on CBD?

It is practically impossible to fatally overdose on CBD. According to the WHO report (2018), no deaths have been recorded due to CBD alone. Clinical studies have tested doses of up to 1500-6000 mg daily without life-threatening risks. However, one can experience intensified side effects: significant drowsiness, diarrhea, dizziness. Optimal consumer doses are 10-50 mg daily.

Will CBD show up on a drug test?

Pure CBD should not yield a positive result in a drug test that detects THC metabolite (THC-COOH). The risk exists when a product contains trace amounts of THC above the declaration – a JAMA study (2017) found that 21% of tested products contained undeclared THC. For professions requiring testing (drivers, emergency services), CBD isolate is safer than full spectrum.

How long does it take for CBD to start working?

The duration of action depends on the form of administration. Sublingual oil works in 15-45 minutes, effects last 4-6 hours. Capsules and edibles take 45-90 minutes but work for 6-8 hours. Vaporizing flower or e-liquid gives effects in 5-10 minutes but shorter duration of 2-3 hours. Therapeutic effects for sleep or anxiety usually appear after 2-4 weeks of regular use.

Does CBD cause addiction?

No. The WHO ECDD report from 2018 clearly states that CBD does not exhibit potential for abuse or dependence ([WHO, 2018](https://www.who.int/publications/i/item/who-ecdd-40-cbd-critical-review)). There are no physiological withdrawal symptoms. In tests involving laboratory animals, behaviors typical of addictive substances, such as self-administration or substance-seeking, were not observed.

Can I drive after taking CBD?

CBD itself does not affect driving ability in a way comparable to alcohol or THC. However, high doses may cause drowsiness, and trace amounts of THC in full-spectrum products may be detected in police drug tests. It is safer to exercise caution: test a new dose first on days when you are not driving and choose CBD isolates if you drive regularly.

How long can CBD be safely used?

There are no time limits for typical consumer doses (10-50 mg/day). Studies on Epidiolex were conducted for 1-2 years without signals of safety issues requiring therapy interruption. However, there is a lack of long-term studies beyond 5 years. A good practice is to take periodic breaks (1-2 weeks every few months) and regular liver function tests when using higher doses long-term.

Is CBD safe for older adults?

Generally yes, but it requires caution. Older adults often take multiple medications, which increases the risk of interactions through CYP3A4 and CYP2C19. According to Brown and Winterstein (2019), individuals on warfarin, statins, antidepressants, and immunosuppressants should be particularly cautious. Recommended starting doses are lower (5-10 mg/day) and mandatory consultation with the attending physician.

Does CBD help with specific ailments or is it placebo?

The strongest evidence pertains to drug-resistant epilepsy (Epidiolex – registered medication). Moderate evidence exists for anxiety, sleep issues, and chronic pain, although most studies are small trials. For other uses (depression, autoimmune diseases, cancers), the data is preliminary or insufficient. CBD is not a panacea, but it has a real, measurable pharmacological effect.

Summary – is CBD safe?

Yes, CBD is a substance with a good safety profile, confirmed by the World Health Organization in its 2018 report. It does not exhibit potential for dependence, does not cause the psychoactive effects typical of THC, and the most common side effects (drowsiness, diarrhea, dry mouth) are mild and transient.

Real risks exist in three areas. First, drug interactions – CBD inhibits CYP3A4 and CYP2C19 enzymes, affecting the metabolism of many medications. Second, product quality – a JAMA study found that 69% of products on the market are mislabeled. Third, pregnancy and breastfeeding – the FDA advises against using CBD during these periods.

Practical conclusions. Start with a low dose of 10-25 mg daily. Choose products with a current COA from an independent laboratory. Consult your doctor if you take chronic medications. Avoid CBD during pregnancy and breastfeeding. Check Polish legal requirements (below 0.3% THC) with every purchase.

If you are interested in specific products with verifiable origin and a certificate of analysis, check out the hemp store u Bucha, where all items have available documents confirming composition and purity.

Disclaimer: The above article is for educational and informational purposes only. It does not constitute medical, diagnostic, or therapeutic advice. Before starting CBD supplementation, especially when taking chronic medications, during pregnancy, breastfeeding, or with existing conditions, consult your doctor or pharmacist. CBD may interact with medications metabolized by the liver enzymes CYP3A4 and CYP2C19. Choose only products from a trusted source with a current Certificate of Analysis (COA). The author and publisher are not responsible for health decisions made based on this text.